ANDA 62421, held by Actavis Labs Fl Inc. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 62421 (Doxycycline Hyclate), held by Actavis Labs Fl Inc, was first approved by FDA on Feb 2, 1983, with 25 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 1983 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Aug 11, 2025 | Supplement 76Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 75Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 70Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 69Labeling · Standard review | Approved | None posted |
| Jan 2, 2018 | Supplement 68Labeling · Standard review | Approved | None posted |
| Jan 2, 2018 | Supplement 67Labeling · Standard review | Approved | None posted |
| Jan 2, 2018 | Supplement 62Labeling · Standard review | Approved | None posted |
| Dec 14, 2012 | Supplement 60Labeling · Standard review | Approved | None posted |
| Jul 28, 2010 | Supplement 52Labeling | Approved | None posted |
| Sep 1, 2005 | Supplement 32Labeling | Approved | None posted |
| Apr 18, 2003 | Supplement 27Labeling | Approved | None posted |
| Dec 23, 2002 | Supplement 28Labeling | Approved | None posted |
| May 1, 2001 | Supplement 25Manufacturing | Approved | None posted |
| Apr 25, 2001 | Supplement 26Manufacturing | Approved | None posted |
| Dec 26, 2000 | Supplement 24Manufacturing | Approved | None posted |
| Aug 9, 2000 | Supplement 23Labeling | Approved | None posted |
| Sep 1, 1993 | Supplement 21Labeling | Approved | None posted |
| Apr 14, 1993 | Supplement 20Labeling | Approved | None posted |
| Oct 23, 1992 | Supplement 19Labeling | Approved | None posted |
| Feb 26, 1992 | Supplement 18Labeling | Approved | None posted |
| May 31, 1991 | Supplement 16Manufacturing | Approved | None posted |
| Nov 15, 1990 | Supplement 17Manufacturing | Approved | None posted |
| Jun 29, 1990 | Supplement 15Manufacturing | Approved | None posted |
| Oct 14, 1988 | Supplement 13Manufacturing | Approved | None posted |
| Sep 1, 1988 | Supplement 12Manufacturing | Approved | None posted |
| Feb 2, 1983 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters